{"id":56729,"date":"2025-12-01T11:08:25","date_gmt":"2025-12-01T15:08:25","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/us-uk-pharmaceutical-deal-gsks-cancer-breakthrough-and-mixed-economic-signals-drive-market-volatility\/56729\/"},"modified":"2025-12-01T11:08:25","modified_gmt":"2025-12-01T15:08:25","slug":"us-uk-pharmaceutical-deal-gsks-cancer-breakthrough-and-mixed-economic-signals-drive-market-volatility","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/us-uk-pharmaceutical-deal-gsks-cancer-breakthrough-and-mixed-economic-signals-drive-market-volatility\/56729\/","title":{"rendered":"US-UK Pharmaceutical Deal, GSK&#8217;s Cancer Breakthrough, and Mixed Economic Signals Drive Market Volatility"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>The U.S. and UK have reached an agreement in principle on pharmaceutical pricing, which will see the UK&#39;s National Health Service (NHS) increase the net price it pays for new medicines by 25% and exempt UK-origin pharmaceuticals from Section 232 tariffs.<\/strong><\/li>\n<li><strong>GSK (<a href=\"\/stock\/GSK\">GSK<\/a>) announced promising long-term data for belantamab mafodotin in treating relapsed\/refractory multiple myeloma at the American Society of Hematology (ASH) meeting, indicating potential to redefine outcomes for blood cancer patients.<\/strong><\/li>\n<li><strong>Global economic data presented a mixed picture, with a stronger-than-expected U.S. S&amp;P Global Manufacturing PMI of 52.2 for November, contrasting with a contraction in Canada&#39;s PMI to 48.4, while U.S. stocks extended declines and Treasury yields rose.<\/strong><\/li>\n<li><strong>Bank of America has revised its Federal Reserve forecast, now anticipating a December rate cut, signaling a potential shift in monetary policy expectations amidst current market movements.<\/strong><\/li>\n<\/ul>\n<p>A significant agreement in principle has been announced between the United States and the United Kingdom regarding pharmaceutical pricing and trade, a move set to reshape the transatlantic pharmaceutical landscape. The deal stipulates that the <strong>UK&#39;s NHS will increase the net price it pays for new medicines by 25%<\/strong>. Furthermore, the U.S. has agreed to <strong>exempt UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from Section 232 tariffs<\/strong>. The U.S. Trade Representative (USTR) also stated that the U.S. will refrain from targeting UK pharmaceutical pricing practices in any future Section 301 investigation for the duration of President Trump&#39;s term.<\/p>\n<p>This agreement is expected to strengthen supply chains and create jobs in the U.S., according to the U.S. Commerce Secretary. The USTR further noted that the deal secured continued investment by UK pharmaceutical companies in the United States and that the U.S. will work to ensure that UK citizens have access to the latest pharmaceutical breakthroughs. USTR Greer indicated that the Trump administration is reviewing pharmaceutical pricing practices of many other U.S. trading partners, hoping they will follow suit with constructive negotiations.<\/p>\n<p>In corporate news, pharmaceutical giant GSK (<a href=\"\/stock\/GSK\">GSK<\/a>) shared encouraging updates from the American Society of Hematology (ASH) meeting. Data presented showed the potential of <strong>belantamab mafodotin<\/strong> to redefine outcomes for individuals living with blood cancers. Specifically, long-term data from the DREAMM-7 and DREAMM-8 studies highlighted the sustained benefits of belantamab mafodotin in the treatment of relapsed\/refractory multiple myeloma. This news could significantly impact GSK&#39;s oncology pipeline and offer new hope for patients.<\/p>\n<p>Economic indicators provided a varied outlook across North America. The <strong>U.S. S&amp;P Global Manufacturing PMI for November finalized at 52.2<\/strong>, exceeding both the estimate and previous reading of 51.9, suggesting robust manufacturing activity. Conversely, Canada&#39;s S&amp;P Global Manufacturing PMI for November declined to 48.4 from a previous 49.6, indicating a contraction in the sector. Meanwhile, <strong>U.S. stocks extended their fall<\/strong>, with the Nasdaq (<a href=\"\/stock\/IXIC\">.IXIC<\/a>) down 1.00%, the <a href=\"https:\/\/stockmarketwatch.com\/indices\/sp500\/today\" data-internallinksmanager029f6b8e52c=\"3\" title=\"snp500 today\">S&amp;P 500<\/a> (<a href=\"\/stock\/SPX\">.SPX<\/a>) down 0.61%, and the <a href=\"https:\/\/stockmarketwatch.com\/indices\/dowjones\/today\" data-internallinksmanager029f6b8e52c=\"1\" title=\"Dow Jones Today\">Dow Jones<\/a> Industrial Average (<a href=\"\/stock\/DJI\">.DJI<\/a>) down 0.59% after market open.<\/p>\n<p>Bond markets also saw upward pressure, with <strong>UK 30-year gilt yields rising 8 basis points to 5.273%<\/strong>, reaching their highest level since November 26. U.S. Treasury yields also extended their rise, with 10-year yields up 6.5 basis points at 4.085%, attributed to corporate bond deal issuance. Amidst these market movements, Bank of America has notably <strong>flipped its Federal Reserve forecast back to a December rate cut<\/strong>, suggesting a potential shift in monetary policy expectations.<\/p>\n<p>In other news, Hero MotoCorp (<a href=\"\/stock\/HEROMOTOCO\">HEROMOTOCO<\/a>) reported strong November total sales of 604,490 units, significantly up from 459,805 units year-over-year and surpassing the estimated 580,080 units. Bank of England&#39;s Catherine L. Greene indicated a potential shift in her view on rates if the outlook for consumer consumption proves much weaker than expected. Additionally, Germany&#39;s Merz announced that Germany is working with Poland to utilize frozen Russian assets and plans to sign a defense agreement in 2026. The UK&#39;s Office for Budget Responsibility (OBR) also launched an investigation into the early release of a fiscal forecast on Budget Day.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways The U.S. and UK have reached an agreement in principle on pharmaceutical pricing, which will see the UK&#39;s [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[6810,157,7503,424,8715,526,15359,4222,15360,4380,15361,5134,5160,5376,5465],"class_list":["post-56729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-ustr","tag-nhs","tag-manufacturing-pmi","tag-gsk","tag-oncology","tag-ash","tag-pharmaceutical-pricing","tag-interest-rates","tag-us-uk-trade","tag-stock-market","tag-blood-cancers","tag-central-banks","tag-economic-data","tag-bond-yields","tag-obr"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/56729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=56729"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/56729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=56729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=56729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=56729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}